PMLiVE3d
PMLiVE’s Top Pharma list
This handy resource ranks the top companies in the pharmaceutical industry by their global sales, as well as by revenues in the US, Europe and Japan. The Top Pharma List also features profile pages ...
PMLiVE5d
Merck KGaA/Abbisko share positive phase 3 results for pimicotinib in rare tumour type
Merck KGaA and Abbisko Therapeutics have announced positive results from a late-stage study of pimicotinib in patients with ...
PMLiVE6d
Is Gen AI ready for life sciences?
The explosive growth of Gen AI has caused plenty of consternation as well as celebration, but there’s no turning back the ...
PMLiVE6d
Direct Express
Direct Express is a well-established company based to the north of London – at Welham Green, Hertfordshire – which is close to the M25, M4, M3, M1 and A1(M).
PMLiVE6d
AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1
AstraZeneca (AZ) and Merck – known as MSD outside the US and Canada – have shared positive results from a late-stage study of ...
PMLiVE6d
J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease
Johnson & Johnson (J&J) has announced that its anti-FcRn antibody nipocalimab has become the first investigational therapy to ...
PMLiVE8d
Novavax announces FDA clinical hold lift on phase 3 COVID-19/flu vaccine study
Novavax has announced that the US Food and Drug Administration (FDA) has lifted its clinical hold on a late-stage study of the company’s COVID-19/influenza combination and stand-alone influenza ...
PMLiVE9d
AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial
AstraZeneca (AZ) and Amgen have shared positive results from a late-stage study of Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The phase 3 WAYPOINT trial ...
PMLiVE9d
FDA approves Autolus Therapeutics’ Aucatzyl to treat acute lymphoblastic leukaemia
The US Food and Drug Administration (FDA) has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel) to treat acute lymphoblastic leukaemia (ALL). The CD19-directed CAR-T cell therapy has ...
PMLiVE9d
Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu
Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous version of its AstraZeneca-partnered antibody-drug conjugate (ADC) Enhertu (fam ...
PMLiVE12d
NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder
The National Institute for Health and Care Excellence (NICE) has recommended Blueprint Medicines’ Ayvakyt (avapritinib) to treat patients with the rare blood disorder systemic mastocytosis (SM). The ...
PMLiVE12d
UK study shows RSV vaccine could reduce antibiotic use and antimicrobial resistance
A UK study has demonstrated that interventions to reduce respiratory syncytial virus (RSV) infections could help to reduce antibiotic prescribing and therefore antimicrobial resistance (AMR), which is ...